---
title: "Status Migrainosus"
description: "Clinical decision support for evaluation and management of status migrainosus"
version: "1.0"
setting: "ED, HOSP, OPD, ICU"
status: draft
tags:
  - headache
  - migraine
  - status-migrainosus
---

<div class="draft-warning-banner">
  <div class="icon">⚠️</div>
  <div class="content">
    <div class="title">DRAFT - Pending Review</div>
    <div class="description">This plan requires physician review before clinical use.</div>
  </div>
</div>

# Status Migrainosus

**VERSION:** 1.0
**CREATED:** January 30, 2026
**REVISED:** January 30, 2026
**STATUS:** Draft - Pending Review

---

**DIAGNOSIS:** Status Migrainosus

**ICD-10:** G43.901 (Migraine, unspecified, not intractable, with status migrainosus), G43.911 (Migraine, unspecified, intractable, with status migrainosus), G43.919 (Migraine, unspecified, intractable, without status migrainosus)

**SYNONYMS:** Status migrainosus, intractable migraine, refractory migraine, prolonged migraine, migraine lasting more than 72 hours, severe intractable migraine, persistent migraine, unrelenting migraine, migraine emergency, debilitating migraine, migraine requiring hospitalization, migraine headache emergency, protracted migraine, treatment-resistant migraine attack, migraine not responding to treatment

**SCOPE:** Evaluation and management of status migrainosus (debilitating migraine lasting >72 hours), including acute abortive therapy, rescue protocols, and prevention of recurrence. Excludes routine migraine management, chronic migraine prophylaxis initiation, cluster headache, and secondary headache disorders.

---

**DEFINITIONS:**
- **Status Migrainosus:** Debilitating migraine attack lasting continuously for more than 72 hours, with or without brief periods of relief (ICHD-3 criteria)
- **Refractory Status Migrainosus:** Status migrainosus not responding to standard first-line parenteral treatments in the ED or hospital
- **Medication Overuse Headache (MOH):** Headache occurring ≥15 days/month in a patient using acute medications regularly for >3 months; a common contributor to status migrainosus
- **Headache Cocktail:** Combination of IV antiemetic (dopamine antagonist) + IV NSAID + IV diphenhydramine, the standard first-line parenteral regimen for acute migraine/status migrainosus in the ED

---

**PRIORITY KEY:** STAT = Immediate | URGENT = Within hours | ROUTINE = Standard | EXT = Extended/atypical cases | - = Not applicable to this setting

---

═══════════════════════════════════════════════════════════════
SECTION A: ACTION ITEMS
═══════════════════════════════════════════════════════════════

## 1. LABORATORY WORKUP

### 1A. Essential/Core Labs

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| CBC with differential (CPT 85025) | Rule out infection, anemia contributing to headache | Normal | STAT | ROUTINE | ROUTINE | STAT |
| CMP (CPT 80053) | Electrolyte abnormalities from dehydration/vomiting; renal function for medication dosing | Normal | STAT | ROUTINE | ROUTINE | STAT |
| Magnesium (CPT 83735) | Hypomagnesemia lowers migraine threshold and is common in status migrainosus | >1.8 mg/dL | STAT | ROUTINE | ROUTINE | STAT |
| Pregnancy test (hCG, women of childbearing age) (CPT 84703) | Pregnancy status affects treatment selection (contraindication to triptans, DHE, valproate) | Document status | STAT | STAT | ROUTINE | STAT |
| TSH (CPT 84443) | Thyroid dysfunction as contributing factor to refractory headache | Normal | - | ROUTINE | ROUTINE | - |

### 1B. Extended Workup (Second-line)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| ESR (CPT 85652) / CRP (CPT 86140) | Rule out giant cell arteritis (age >50, new-onset) or inflammatory etiology | Normal | URGENT | ROUTINE | ROUTINE | URGENT |
| Vitamin D (CPT 82306) | Deficiency associated with increased migraine frequency and chronification | >30 ng/mL | - | ROUTINE | ROUTINE | - |
| Ferritin (CPT 82728) | Iron deficiency associated with migraine; may contribute to refractoriness | >50 ng/mL | - | ROUTINE | ROUTINE | - |
| LFTs (AST, ALT, Alk Phos) (CPT 80076) | Baseline before valproate or repeated NSAID use | Normal | URGENT | ROUTINE | ROUTINE | URGENT |
| Ammonia (CPT 82140) | Baseline before valproate; elevated levels worsen encephalopathy | <35 micromol/L | URGENT | ROUTINE | - | URGENT |
| Blood gas (VBG) (CPT 82803) | Assess for metabolic derangement in prolonged vomiting/dehydration | Normal pH, bicarbonate | URGENT | ROUTINE | - | STAT |

### 1C. Rare/Specialized (Refractory or Atypical)

| Test | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|------|-----------|----------------|:--:|:----:|:---:|:---:|
| Urine drug screen (CPT 80307) | Occult substance use contributing to headache; medication overuse | Negative for unexpected substances | URGENT | ROUTINE | EXT | URGENT |
| Blood cultures (CPT 87040) | If fever present or meningitis suspected | No growth | URGENT | URGENT | - | STAT |
| Autoimmune panel (ANA (CPT 86235), ESR, CRP) | Suspected vasculitis or autoimmune etiology in atypical presentation | Negative | - | EXT | EXT | EXT |
| Lactate (CPT 83605) | If sepsis or meningitis suspected | <2 mmol/L | URGENT | URGENT | - | STAT |
| Homocysteine (CPT 83090) | Elevated levels associated with migraine with aura; refractory cases | Normal | - | - | EXT | - |

---

## 2. DIAGNOSTIC IMAGING & STUDIES

### 2A. Essential/First-line

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| CT head without contrast (CPT 70450) | Immediate if thunderclap onset, new focal deficit, altered mental status, worst headache of life | Rule out hemorrhage, mass, hydrocephalus | None in emergency | STAT | URGENT | - | STAT |
| ECG (CPT 93000) | Before DHE, triptan, or antiemetic administration | Normal QTc (<470 ms women, <450 ms men), no ischemia | None | STAT | STAT | ROUTINE | STAT |

### 2B. Extended

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| MRI brain without contrast (CPT 70551) | When stable; new headache pattern, refractory to treatment, atypical features | Normal; rule out structural lesion, pituitary apoplexy, Chiari malformation | Pacemaker, metal implants | - | ROUTINE | ROUTINE | - |
| MRI brain with and without contrast (CPT 70553) | If mass, infection, inflammation, or venous thrombosis suspected | Rule out enhancement, meningeal disease | Contrast allergy, severe renal disease | - | ROUTINE | ROUTINE | - |
| MRV or CT venogram (CPT 70547 or 70498) | If cerebral venous thrombosis suspected (postpartum, OCP use, papilledema) | Patent venous sinuses | Per modality | URGENT | URGENT | ROUTINE | URGENT |
| MRA head (CPT 70544) | If vasculopathy or aneurysm suspected | Normal vasculature | Per modality | - | ROUTINE | ROUTINE | - |
| Fundoscopic exam | All patients; assess for papilledema suggesting elevated ICP | Normal optic discs | None | STAT | STAT | ROUTINE | STAT |

### 2C. Rare/Specialized

| Study | Timing | Target Finding | Contraindications | ED | HOSP | OPD | ICU |
|-------|--------|----------------|-------------------|:--:|:----:|:---:|:---:|
| CTA head and neck (CPT 70496, 70498) | If cervical artery dissection suspected (neck pain, Horner syndrome) | No dissection | Contrast allergy, renal disease | URGENT | URGENT | - | URGENT |
| Temporal artery ultrasound | Age >50, elevated ESR, suspected GCA | No halo sign | None | - | ROUTINE | ROUTINE | - |

### LUMBAR PUNCTURE (CPT 62270)

**Indication:** Thunderclap headache, suspected SAH (CT negative), suspected IIH (papilledema), suspected meningitis, fever with headache, immunocompromised patient
**Timing:** URGENT after CT excludes mass effect
**Volume Required:** 10-15 mL standard diagnostic

| Study | Rationale | Target Finding | ED | HOSP | OPD | ICU |
|-------|-----------|----------------|:--:|:----:|:---:|:---:|
| Opening pressure | Rule out elevated ICP (IIH) or low-pressure headache | 10-20 cm H2O | STAT | STAT | - | STAT |
| Cell count (tubes 1 and 4) (CPT 89051) | Infection, SAH | WBC <5; RBC 0 or clearing | STAT | STAT | - | STAT |
| Protein (CPT 84157) | Infection, inflammation | 15-45 mg/dL | STAT | STAT | - | STAT |
| Glucose with serum glucose (CPT 82945) | Infection (low in bacterial/fungal) | >60% serum glucose | STAT | STAT | - | STAT |
| Xanthochromia | SAH if CT negative and >12 hours from onset | Negative | STAT | STAT | - | STAT |
| Gram stain and culture (CPT 87205, 87070) | Bacterial meningitis | No organisms | STAT | STAT | - | STAT |

**Special Handling:** Xanthochromia requires light-protected transport. Cell count within 1 hour.
**Contraindications:** Signs of herniation, coagulopathy (INR >1.5, platelets <50K), skin infection at LP site. CT before LP if any concern for mass effect.

---

## 3. TREATMENT

**CRITICAL: Status migrainosus requires stepwise escalation. Start with the "headache cocktail" and escalate as needed. Each medication must be on its own row with complete dosing.**

### 3A. Acute/First-Line - IV Rehydration and "Headache Cocktail"

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Normal saline IV | IV | Rehydration; prolonged vomiting and poor oral intake common in status migrainosus | 1000 mL bolus; 75-125 mL/hr :: IV :: once :: NS 1L bolus over 1-2h, then 75-125 mL/hr maintenance | Heart failure, volume overload | I/O, signs of fluid overload | STAT | STAT | - | STAT |
| Lactated Ringer's IV | IV | Alternative IV fluid for rehydration with electrolyte replacement | 1000 mL bolus; 75-125 mL/hr :: IV :: once :: LR 1L bolus over 1-2h, then 75-125 mL/hr maintenance | Heart failure, hyperkalemia | I/O, electrolytes | STAT | STAT | - | STAT |
| Prochlorperazine IV | IV | First-line antiemetic and primary analgesic for acute migraine via dopamine antagonism | 10 mg IV once :: IV :: once :: 10 mg IV slow push over 5-10 min; may repeat x1 in 30 min; max 20 mg | QT prolongation (QTc >500 ms), Parkinson disease, pheochromocytoma | QTc, akathisia, dystonic reaction, sedation | STAT | STAT | - | STAT |
| Metoclopramide IV | IV | First-line antiemetic and primary analgesic for acute migraine via dopamine antagonism; alternative to prochlorperazine | 10 mg IV once; 20 mg IV once :: IV :: once :: 10-20 mg IV over 15-30 min; may repeat x1 in 30 min; max 40 mg | QT prolongation, Parkinson disease, seizure disorder, bowel obstruction | QTc, akathisia, dystonic reaction, sedation | STAT | STAT | - | STAT |
| Diphenhydramine IV | IV | Prevention of akathisia and dystonic reactions from dopamine antagonist antiemetics | 25 mg IV once; 50 mg IV once :: IV :: once :: 25-50 mg IV push with each antiemetic dose | Narrow-angle glaucoma, urinary retention, severe drowsiness risk | Sedation level | STAT | STAT | - | STAT |
| Ketorolac IV | IV | Potent parenteral NSAID for acute pain relief; synergistic with antiemetics | 30 mg IV once; 15 mg IV once :: IV :: once :: 30 mg IV push (15 mg if age >65, CrCl <50, or weight <50 kg); max 2 doses in 24h; max 5 days total | Active GI bleeding, renal insufficiency (CrCl <30), coagulopathy, concurrent anticoagulation, third trimester pregnancy | Renal function, GI symptoms, bleeding | STAT | STAT | - | STAT |
| Dexamethasone IV | IV | Prevention of headache recurrence within 72 hours; does not treat acute pain | 10 mg IV once :: IV :: once :: 10 mg IV once; single dose (NNT 9 for recurrence prevention) | Active untreated infection, uncontrolled diabetes mellitus | Blood glucose (check at 4-6h), mood changes | URGENT | URGENT | - | URGENT |
| Magnesium sulfate IV | IV | Direct analgesic effect in migraine; low magnesium lowers cortical spreading depression threshold | 2 g IV once :: IV :: once :: 2 g IV in 50 mL NS over 20-30 min | Renal failure (GFR <30), myasthenia gravis, heart block | Magnesium level, deep tendon reflexes, respiratory status, flushing | URGENT | URGENT | - | URGENT |

### 3B. Second-Line Acute Treatments

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Sumatriptan SC | SC | Triptan-naive or triptan-responsive patients without vascular contraindications; most effective when given early | 6 mg SC once :: SC :: once :: 6 mg SC once; may repeat x1 in 2h; max 12 mg/24h | CAD, prior stroke/TIA, uncontrolled hypertension (>140/90), hemiplegic or basilar migraine, pregnancy, use of ergotamine/DHE within 24h, concurrent MAOI | Chest tightness, blood pressure, coronary symptoms | STAT | STAT | - | STAT |
| Sumatriptan nasal | IN | Alternative triptan route when SC not tolerated or for moderate attacks | 20 mg IN once :: IN :: once :: 20 mg intranasal; may repeat in 2h; max 40 mg/24h | Same as sumatriptan SC | Same as sumatriptan SC | URGENT | URGENT | ROUTINE | URGENT |
| Valproate sodium IV | IV | Acute migraine treatment for patients who cannot receive triptans/DHE or as adjunct; also anti-nausea properties | 500 mg IV once; 1000 mg IV once :: IV :: once :: 500-1000 mg IV over 15-30 min; may repeat once in 8h | Pregnancy (teratogenic - neural tube defects), hepatic disease, mitochondrial disease (POLG mutation), urea cycle disorders, pancreatitis | Ammonia, LFTs, platelet count | URGENT | URGENT | - | URGENT |
| Chlorpromazine IV | IV | Alternative dopamine antagonist with potent analgesic and sedative effect for refractory migraine | 12.5 mg IV once; 25 mg IV once :: IV :: once :: 12.5-25 mg IV over 20 min with 500 mL NS bolus; may repeat x2 q30min; max 75 mg | QT prolongation, severe hypotension, Parkinson disease | BP q15min (orthostatic hypotension common), QTc, sedation | URGENT | URGENT | - | URGENT |
| Droperidol IV | IV | Alternative dopamine antagonist with strong antiemetic and analgesic effect; FDA black box for QT prolongation requires ECG | 2.5 mg IV once :: IV :: once :: 2.5 mg IV over 2-5 min; may repeat x1 in 30 min; max 5 mg | QT prolongation (QTc >440 ms), hypokalemia, hypomagnesemia, Parkinson disease | ECG before and after (FDA black box), QTc, BP, akathisia | URGENT | URGENT | - | URGENT |
| Ondansetron IV | IV | Antiemetic for nausea/vomiting when dopamine antagonists contraindicated (Parkinson disease) | 4 mg IV once; 8 mg IV once :: IV :: once :: 4-8 mg IV over 2-5 min; may repeat q6-8h; max 32 mg/24h | QT prolongation (dose-dependent), concurrent serotonergic drugs (caution) | QTc at higher doses | URGENT | ROUTINE | ROUTINE | URGENT |
| Greater occipital nerve block | Local | Acute pain relief and potential sustained benefit (3-4 weeks); safe in pregnancy | 2-3 mL per side :: Local :: once :: Bupivacaine 0.5% 2-3 mL per side (bilateral) at greater occipital nerve; may add triamcinolone 20 mg per side | Local anesthetic allergy, infection at injection site, concurrent anticoagulation (relative) | Local reaction, vasovagal response | URGENT | ROUTINE | ROUTINE | URGENT |
| Supraorbital nerve block | Local | Additional peripheral nerve block targeting frontal headache distribution | 1-2 mL per side :: Local :: once :: Bupivacaine 0.5% 1-2 mL per side at supraorbital notch | Local anesthetic allergy, infection at site | Local reaction | - | ROUTINE | ROUTINE | - |

### 3C. Refractory/Third-Line - DHE Protocol and Rescue Therapies

**DHE Prerequisites:** Confirm normal ECG, BP <140/90, negative pregnancy test. Do NOT administer if triptan given within 24 hours or history of CAD/CVA/PAD. Premedicate with antiemetic.

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Dihydroergotamine (DHE) IV - test dose | IV | First dose to assess tolerability before initiating repetitive DHE protocol | 0.5 mg IV once :: IV :: once :: Premedicate: metoclopramide 10 mg IV + diphenhydramine 25 mg IV 30 min prior; then DHE 0.5 mg IV over 3-5 min as test dose | Pregnancy, CAD, CVA, PVD, uncontrolled HTN (>180/110), triptan within 24h, ergot allergy, basilar/hemiplegic migraine, severe hepatic or renal disease, concurrent CYP3A4 inhibitors | BP q15min during infusion, chest pain, limb ischemia, nausea | URGENT | STAT | - | URGENT |
| Dihydroergotamine (DHE) IV - repetitive protocol | IV | Repetitive IV DHE for sustained break of status migrainosus (Raskin protocol) | 0.5 mg IV q8h; 1 mg IV q8h :: IV :: q8h :: If test dose tolerated: 0.5-1 mg IV q8h for up to 3-5 days; premedicate each dose with antiemetic; may titrate to 1 mg if 0.5 mg tolerated | Same as test dose | Same as test dose; daily ECG during protocol | - | STAT | - | URGENT |
| DHE nasal spray | IN | Alternative to IV DHE for patients who decline IV protocol or as bridge to outpatient | 0.5 mg per nostril once :: IN :: once :: 0.5 mg per nostril (1 mg total); may repeat once in 15 min; max 3 mg/24h; max 4 mg/week | Same as IV DHE | Nausea, nasal congestion | - | ROUTINE | ROUTINE | - |
| Ketamine IV sub-anesthetic | IV | Refractory status migrainosus not responding to standard therapies; NMDA receptor antagonism disrupts central sensitization | 0.1 mg/kg bolus; 0.1-0.5 mg/kg/hr :: IV :: continuous :: 0.1 mg/kg IV bolus, then 0.1-0.5 mg/kg/hr infusion; titrate by 0.1 mg/kg/hr q30min; max 1 mg/kg/hr; typical duration 24-48h | Uncontrolled hypertension, active psychosis, elevated ICP (relative), age <18 | BP, HR (may increase), dissociative symptoms, nystagmus, sedation level, psychiatric effects | - | EXT | - | URGENT |
| Propofol sub-anesthetic bolus | IV | Brief burst-like suppression of migraine pain via GABA modulation; requires monitored setting | 20-30 mg IV once :: IV :: once :: 20-30 mg IV bolus; may repeat q5min up to 100 mg total; must have respiratory monitoring | Egg/soy allergy, hemodynamic instability, respiratory compromise without airway support | O2 sat, BP, respiratory status; requires procedural sedation monitoring | - | EXT | - | URGENT |
| Lidocaine IV infusion | IV | Sodium channel blockade for refractory status migrainosus; typically inpatient protocol | 1-2 mg/kg bolus; 1-2 mg/min :: IV :: continuous :: Load 1-2 mg/kg IV over 20 min, then 1-2 mg/min (60-120 mg/hr) infusion x 24-48h | Heart block, severe CHF, hepatic failure | Continuous cardiac monitoring, lidocaine level q12h (target <5 mcg/mL), neuro checks for toxicity (perioral numbness, tinnitus, seizures) | - | EXT | - | EXT |

### 3D. Adjunctive Treatments and Recurrence Prevention

| Treatment | Route | Indication | Dosing | Contraindications | Monitoring | ED | HOSP | OPD | ICU |
|-----------|-------|------------|--------|-------------------|------------|:--:|:----:|:---:|:---:|
| Dexamethasone PO taper | PO | Prevention of headache recurrence after ED/hospital discharge; bridge to preventive therapy | 4 mg BID x 4 days :: PO :: BID :: 4 mg PO BID x 4 days; may taper over 1 week | Active infection, uncontrolled DM, GI ulcer | Blood glucose, GI symptoms, mood | - | ROUTINE | ROUTINE | - |
| Naproxen sodium PO | PO | Transitional therapy for recurrence prevention after discharge; scheduled dosing more effective than PRN | 500 mg BID :: PO :: BID :: 500 mg PO BID with food x 5-7 days as bridge | GI bleeding, renal disease, third trimester pregnancy | Renal function, GI symptoms | - | ROUTINE | ROUTINE | - |
| Acetaminophen IV | IV | Mild-moderate pain adjunct when NSAIDs contraindicated; pregnancy-safe option | 1000 mg IV q6h :: IV :: q6h :: 1000 mg IV q6h; max 3000 mg/day (2000 mg/day if hepatic risk) | Severe hepatic disease (Child-Pugh C), chronic alcohol use (>3 drinks/day) | LFTs if repeated use >3 days | URGENT | ROUTINE | - | URGENT |
| Methylprednisolone IV | IV | Alternative to dexamethasone for acute anti-inflammatory effect in severe cases | 125 mg IV once :: IV :: once :: 125 mg IV once | Active infection, uncontrolled DM | Blood glucose, mood | URGENT | URGENT | - | URGENT |
| Promethazine IV/IM | IV, IM | Antiemetic and sedative adjunct for nausea-predominant status migrainosus when other antiemetics inadequate | 12.5 mg IV once; 25 mg IM once :: IV, IM :: once :: 12.5-25 mg IV slow push (over 10-15 min to reduce phlebitis) or 25 mg deep IM; may repeat q4-6h; max 75 mg/day | QT prolongation, respiratory depression (especially with opioids), tissue necrosis risk with IV extravasation | Sedation, respiratory status, IV site (severe vesicant) | URGENT | ROUTINE | - | URGENT |
| Triptans PO (for post-discharge rescue) | PO | Outpatient rescue for breakthrough migraine after discharge from status migrainosus treatment | Per specific triptan :: PO :: PRN :: Sumatriptan 100 mg PO, rizatriptan 10 mg PO, or eletriptan 40 mg PO; use within first hour of recurrence; limit to ≤9 days/month | CAD, prior stroke/TIA, uncontrolled HTN, hemiplegic migraine, concurrent ergot/DHE | Cardiovascular symptoms | - | ROUTINE | ROUTINE | - |

---

## 4. OTHER RECOMMENDATIONS

### 4A. Referrals & Consults

| Recommendation | ED | HOSP | OPD | ICU |
|----------------|:--:|:----:|:---:|:---:|
| Neurology consult for diagnosis confirmation, treatment escalation guidance, and preventive strategy | URGENT | ROUTINE | - | URGENT |
| Headache specialist referral for chronic migraine management and refractory status migrainosus | - | ROUTINE | ROUTINE | - |
| Pain management consult for refractory cases not responding to standard protocols, nerve block consideration | - | ROUTINE | ROUTINE | URGENT |
| Ophthalmology consult if papilledema found on fundoscopic exam to rule out IIH | URGENT | URGENT | ROUTINE | URGENT |
| Psychiatry or behavioral health referral for comorbid anxiety, depression, or significant psychosocial stressors contributing to refractoriness | - | ROUTINE | ROUTINE | - |
| Social work consult for discharge planning, outpatient resource coordination, and insurance authorization for specialty medications | - | ROUTINE | ROUTINE | - |
| Physical therapy referral for cervicogenic component evaluation, trigger point therapy, and postural correction | - | - | ROUTINE | - |
| Infusion center referral for outpatient DHE or ketamine infusion protocol if refractory | - | ROUTINE | ROUTINE | - |

### 4B. Patient/Family Instructions

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Return immediately if thunderclap headache onset, fever, neck stiffness, new neurologic deficits, or altered mental status develop (may indicate secondary cause requiring emergency evaluation) | ROUTINE | ROUTINE | ROUTINE |
| Return to ED if headache recurs at severe intensity within 72 hours of discharge despite rescue medications (may require repeat parenteral therapy) | ROUTINE | ROUTINE | ROUTINE |
| Treat recurrent migraine within the first hour of onset for maximal medication efficacy (early treatment is more effective than delayed treatment) | ROUTINE | ROUTINE | ROUTINE |
| Avoid medication overuse: limit triptans to no more than 9 days per month and NSAIDs to no more than 14 days per month to prevent medication overuse headache | ROUTINE | ROUTINE | ROUTINE |
| Keep a detailed headache diary documenting frequency, severity (0-10), triggers, medications used, and response to treatment for follow-up appointments | - | ROUTINE | ROUTINE |
| Follow up with neurology or headache specialist within 2-4 weeks of discharge for preventive therapy initiation and treatment plan adjustment | ROUTINE | ROUTINE | ROUTINE |
| Do not drive until headache has fully resolved and no sedating medications are on board due to impaired reaction time and concentration | ROUTINE | ROUTINE | ROUTINE |
| Take all prescribed discharge medications as directed and do not abruptly discontinue steroids if prescribed a taper (may cause rebound headache or adrenal insufficiency) | ROUTINE | ROUTINE | ROUTINE |

### 4C. Lifestyle & Prevention

| Recommendation | ED | HOSP | OPD |
|----------------|:--:|:----:|:---:|
| Maintain a regular sleep schedule of 7-8 hours per night as both sleep deprivation and oversleeping are established migraine triggers | - | ROUTINE | ROUTINE |
| Regular aerobic exercise (30 minutes, 5 days per week) reduces migraine frequency through endorphin release and stress reduction | - | ROUTINE | ROUTINE |
| Stress management with biofeedback, progressive muscle relaxation, or cognitive behavioral therapy (Level A evidence for migraine prevention) | - | ROUTINE | ROUTINE |
| Stay well-hydrated with at least 64 ounces of water daily as dehydration is a common and modifiable migraine trigger | ROUTINE | ROUTINE | ROUTINE |
| Avoid known dietary triggers including alcohol (especially red wine), aged cheeses, MSG, processed meats, and skipped meals | - | ROUTINE | ROUTINE |
| Limit caffeine to consistent moderate intake (less than 200 mg per day) and avoid abrupt caffeine withdrawal which is a potent headache trigger | - | ROUTINE | ROUTINE |
| Discuss preventive medication initiation at follow-up if experiencing 4 or more migraine days per month, significant disability, or recurrent status migrainosus episodes | - | ROUTINE | ROUTINE |
| Identify and manage comorbid conditions that worsen migraine including depression, anxiety, insomnia, and obesity | - | ROUTINE | ROUTINE |

---

═══════════════════════════════════════════════════════════════
SECTION B: REFERENCE (Expand as Needed)
═══════════════════════════════════════════════════════════════

## 5. DIFFERENTIAL DIAGNOSIS

| Alternative Diagnosis | Key Distinguishing Features | Tests to Differentiate |
|-----------------------|----------------------------|------------------------|
| Subarachnoid hemorrhage | Thunderclap onset ("worst headache of life"), neck stiffness, rapid deterioration, no prior migraine history | CT head (sensitivity >95% within 6h); LP if CT negative (xanthochromia) |
| Cerebral venous thrombosis | Progressive headache, seizures, focal deficits, risk factors (OCP, pregnancy, prothrombotic state), papilledema | MRV or CT venogram; D-dimer (low sensitivity) |
| Idiopathic intracranial hypertension | Papilledema, visual obscurations, pulsatile tinnitus, bilateral pressure headache worse with Valsalva; often obese women | Fundoscopic exam, LP with elevated opening pressure (>25 cm H2O), MRI with empty sella/optic nerve sheath distension |
| Cervical artery dissection | Acute neck pain, Horner syndrome (miosis, ptosis), preceding trauma or neck manipulation, focal neurologic deficits | CTA head/neck or MRA with fat-suppressed sequences |
| Giant cell arteritis | Age >50, new-onset headache, jaw claudication, scalp tenderness, visual symptoms, constitutional symptoms | ESR/CRP markedly elevated; temporal artery biopsy; temporal artery ultrasound (halo sign) |
| Medication overuse headache | Chronic daily headache (≥15 days/month), frequent acute medication use (>10-15 days/month for >3 months), headache worsens with continued overuse | Detailed medication diary; headache improves within 2 months of medication withdrawal |
| Meningitis/encephalitis | Fever, neck stiffness, photophobia, altered mental status, rash (meningococcal); may present subacutely | LP (cell count, protein, glucose, culture, PCR); blood cultures |
| Brain tumor | Progressive headache worse in morning or with Valsalva, new focal deficits, papilledema, weight loss, seizures | MRI brain with contrast |
| Hypertensive emergency | BP >180/120 with headache, visual changes, encephalopathy, end-organ damage | BP measurement, fundoscopic exam, renal function, troponin |
| Pituitary apoplexy | Sudden severe headache, visual field deficits (bitemporal hemianopia), ophthalmoplegia, known or unknown pituitary adenoma | MRI brain with pituitary protocol; hormone levels (cortisol, TSH, prolactin) |
| Spontaneous intracranial hypotension | Orthostatic headache (better lying down, worse upright), may have neck stiffness, subdural fluid collections | MRI brain with contrast (diffuse pachymeningeal enhancement, brain sagging); LP with low opening pressure |
| Reversible cerebral vasoconstriction syndrome | Recurrent thunderclap headaches, may mimic SAH, associated with vasoactive substances or postpartum | CTA/MRA (segmental vasoconstriction); may require repeat imaging as vasoconstriction evolves |

## 6. MONITORING PARAMETERS

| Parameter | Frequency | Target/Threshold | Action if Abnormal | ED | HOSP | OPD | ICU |
|-----------|-----------|------------------|-------------------|:--:|:----:|:---:|:---:|
| Pain scale (0-10 NRS) | q1h during treatment, q4h if stable | Trending toward 0-3/10 | Escalate to next treatment tier | STAT | ROUTINE | Each visit | STAT |
| Vital signs (BP, HR, RR, O2 sat, Temp) | q15min during IV infusions, q4h when stable | BP <140/90, HR 60-100, Temp <38°C | Address abnormality; hypertension may drive headache | STAT | ROUTINE | Each visit | STAT |
| ECG/QTc | Before dopamine antagonist or DHE; repeat if QT-prolonging agents used | QTc <470 ms (women), <450 ms (men) | Avoid QT-prolonging medications; correct electrolytes | STAT | STAT | - | STAT |
| Nausea/vomiting severity | With each pain assessment | Resolution of nausea/vomiting | Add or change antiemetic | STAT | ROUTINE | Each visit | STAT |
| Oral intake tolerance | q4-8h | Tolerating PO fluids and medications | Continue IV hydration; delay discharge | URGENT | ROUTINE | - | ROUTINE |
| Blood glucose (if on steroids) | q6h while on dexamethasone/methylprednisolone | <200 mg/dL | Sliding scale insulin; adjust steroid dose | URGENT | ROUTINE | Each visit | STAT |
| Magnesium level (if supplemented) | After IV magnesium; daily if repletion ongoing | 1.8-2.5 mg/dL | Replete if low; hold if >3.0 mg/dL | URGENT | ROUTINE | ROUTINE | ROUTINE |
| Neurologic exam | At each encounter; after treatment changes | No new focal deficits, improving cognition | Urgent imaging if new deficits; reassess diagnosis | STAT | ROUTINE | Each visit | STAT |
| Akathisia/EPS assessment | 30 min after each antiemetic dose | No restlessness or dystonia | Diphenhydramine 25-50 mg IV; switch antiemetic class | STAT | ROUTINE | - | STAT |
| Headache diary (MIDAS or HIT-6) | Outpatient visits | Improving disability score | Adjust preventive therapy; consider specialist referral | - | - | Each visit | - |

## 7. DISPOSITION CRITERIA

| Disposition | Criteria |
|-------------|----------|
| Discharge from ED | Pain controlled to tolerable level (NRS ≤4/10); tolerating oral fluids and medications; no red flag features; able to ambulate; rescue medication and follow-up plan provided; headache diary instructions given |
| Admit to hospital (observation or floor) | Status migrainosus unresponsive to ED headache cocktail (2 or more treatment rounds); inability to tolerate oral intake despite antiemetics; need for repetitive IV DHE protocol; severe dehydration requiring ongoing IV fluids; concern for secondary headache requiring further workup |
| Admit to ICU | Refractory status migrainosus requiring ketamine infusion or sub-anesthetic propofol; hemodynamic instability from treatments (severe hypotension from chlorpromazine); altered mental status not explained by medications; suspected secondary cause requiring ICU-level monitoring |
| Transfer to higher level of care | Need for services unavailable at current facility (headache specialist, DHE protocol capability, interventional procedures) |
| Discharge from hospital | Pain controlled on oral medications (NRS ≤3/10 for ≥12 hours); tolerating oral fluids and solid food; ambulatory without significant dizziness; discharge medications reviewed with patient; follow-up with neurology arranged within 2-4 weeks |
| Outpatient follow-up intervals | Post-discharge: 2-4 weeks for treatment assessment; Chronic migraine: q1-3 months; Stable on preventive: q3-6 months |

## 8. EVIDENCE & REFERENCES

| Recommendation | Evidence Level | Source |
|----------------|----------------|--------|
| IV prochlorperazine and metoclopramide are effective acute treatments for migraine in the ED | Class I, Level A | [Friedman et al. Ann Emerg Med 2008](https://pubmed.ncbi.nlm.nih.gov/18006188/); [Kelley & Tepper. Headache 2012](https://pubmed.ncbi.nlm.nih.gov/22946834/) |
| IV metoclopramide 10-20 mg superior to placebo for acute migraine | Class I, Level A | [Friedman et al. Neurology 2014](https://pubmed.ncbi.nlm.nih.gov/25009204/) |
| Single-dose IV dexamethasone reduces headache recurrence within 72 hours (NNT 9) | Class I, Level A | [Singh et al. Acad Emerg Med 2008](https://pubmed.ncbi.nlm.nih.gov/18976336/); [Colman et al. BMJ 2008](https://pubmed.ncbi.nlm.nih.gov/18569933/) |
| Ketorolac IV effective for acute migraine; comparable to opioids without sedation | Class I, Level B | [Friedman et al. Headache 2008](https://pubmed.ncbi.nlm.nih.gov/18377386/) |
| IV magnesium sulfate effective for acute migraine, especially with aura | Class I, Level B | [Bigal et al. Headache 2002](https://pubmed.ncbi.nlm.nih.gov/12390634/); [Chiu et al. Ann Emerg Med 2016](https://pubmed.ncbi.nlm.nih.gov/27017579/) |
| Subcutaneous sumatriptan 6 mg effective for acute migraine | Class I, Level A | [Ferrari et al. Lancet 2001](https://pubmed.ncbi.nlm.nih.gov/11742007/) |
| Repetitive IV DHE effective for breaking status migrainosus | Class II, Level B | [Raskin. Neurology 1986](https://pubmed.ncbi.nlm.nih.gov/3520384/); [Nagy et al. Headache 1993](https://pubmed.ncbi.nlm.nih.gov/8436511/) |
| Greater occipital nerve block effective for acute migraine and status migrainosus | Class II, Level B | [Afridi et al. Headache 2006](https://pubmed.ncbi.nlm.nih.gov/17115982/); [Inan et al. J Headache Pain 2015](https://pubmed.ncbi.nlm.nih.gov/25916334/) |
| Valproate IV effective for acute migraine in ED | Class I, Level B | [Tanen et al. Ann Emerg Med 2003](https://pubmed.ncbi.nlm.nih.gov/12883516/) |
| Chlorpromazine IV effective for acute migraine in ED | Class I, Level B | [Kelly et al. Ann Emerg Med 2017](https://pubmed.ncbi.nlm.nih.gov/28601267/) |
| Sub-anesthetic ketamine infusion for refractory migraine | Class III, Level C | [Pomeroy et al. Headache 2017](https://pubmed.ncbi.nlm.nih.gov/28862769/); [Schwenk et al. Reg Anesth Pain Med 2018](https://pubmed.ncbi.nlm.nih.gov/29469714/) |
| IV lidocaine for refractory migraine and status migrainosus | Class III, Level C | [Williams & Bhatt. Anesthesiology 2007](https://pubmed.ncbi.nlm.nih.gov/17413916/); [Rosen et al. Cephalalgia 2009](https://pubmed.ncbi.nlm.nih.gov/19438917/) |
| Diphenhydramine co-administration prevents akathisia from dopamine antagonists | Class II, Level B | [Vinson. Ann Emerg Med 2004](https://pubmed.ncbi.nlm.nih.gov/15226072/) |
| ICHD-3 diagnostic criteria for status migrainosus | Consensus | [ICHD-3. Cephalalgia 2018](https://pubmed.ncbi.nlm.nih.gov/29368949/) |
| AHS consensus statement on migraine treatment in the ED | Consensus/Guidelines | [American Headache Society. Headache 2016](https://pubmed.ncbi.nlm.nih.gov/27300483/) |
| Lifestyle modifications (sleep, exercise, stress management) reduce migraine frequency | Class I, Level B | [AAN/AHS Practice Guidelines, Silberstein et al. Neurology 2012](https://pubmed.ncbi.nlm.nih.gov/22529202/) |

---

## NOTES

- Status migrainosus is defined by ICHD-3 as a debilitating migraine attack lasting >72 hours; severity warrants parenteral treatment
- The "headache cocktail" (IV dopamine antagonist + IV NSAID + IV diphenhydramine) is first-line and should be administered promptly upon arrival
- Dexamethasone (single 10 mg IV dose) reduces recurrence but does not treat acute pain; give alongside the headache cocktail
- IV magnesium is safe and effective, particularly in patients with migraine with aura or low magnesium levels
- Always check ECG before administering DHE, triptans, or QT-prolonging antiemetics
- DHE and triptans must NOT be given within 24 hours of each other due to risk of vasospasm
- Opioids should be AVOIDED in status migrainosus: they increase ED return visits, worsen long-term outcomes, and contribute to medication overuse headache
- Screen for medication overuse headache as a common contributing factor to status migrainosus
- Pregnancy: Acetaminophen, metoclopramide, ondansetron (caution 1st trimester), magnesium, and nerve blocks are safest; avoid triptans, DHE, valproate, and NSAIDs (3rd trimester)
- All patients discharged after status migrainosus should have neurology follow-up within 2-4 weeks and consideration of preventive therapy

---

## CHANGE LOG

**v1.0 (January 30, 2026)**
- Initial template creation
- Comprehensive first-line "headache cocktail" protocol with IV rehydration
- Second-line treatments including triptans, valproate IV, nerve blocks, and alternative antiemetics
- Refractory/third-line treatments including DHE protocol (Raskin), sub-anesthetic ketamine, propofol, and IV lidocaine
- Adjunctive treatments and recurrence prevention (steroids, transitional therapy)
- Full differential diagnosis for prolonged headache (12 diagnoses)
- Evidence-based references with PubMed links
- Setting coverage across ED, HOSP, OPD, ICU
- Structured dosing format for all medications
